A bill to require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable.

referredUnited States· United States Congress· EN

Introduced

10 May 2023

Last action

—

Status

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary

This bill requires the Food and Drug Administration to report on its designation of biosimilars as interchangeable, including the applicable standards, authorities, evidence, and other factors involved in such designations. (Biosimilars that are designated as interchangeable may be substituted for the reference product at a pharmacy without a new prescription, depending on state pharmacy laws.)

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

3 official files

Introduced in Senate (text)

View file Download file

Introduced in Senate (text)
Introduced in Senate · EN · 10 May 2023
View Download Open at official source
Introduced in Senate (PDF)
Introduced in Senate · EN · 10 May 2023
View Download Open at official source
Introduced in Senate
summary · EN · 10 May 2023
Open at official source

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.

Official source: https://www.congress.gov/bill/118th-congress/senate-bill/1522
Open data entity: https://api.congress.gov/v3/bill/118/s/1522